313 related articles for article (PubMed ID: 29668904)
1. A whole brain longitudinal study in the YAC128 mouse model of Huntington's disease shows distinct trajectories of neurochemical, structural connectivity and volumetric changes.
Petrella LI; Castelhano JM; Ribeiro M; Sereno JV; Gonçalves SI; Laço MN; Hayden MR; Rego AC; Castelo-Branco M
Hum Mol Genet; 2018 Jun; 27(12):2125-2137. PubMed ID: 29668904
[TBL] [Abstract][Full Text] [Related]
2. Differential changes in thalamic and cortical excitatory synapses onto striatal spiny projection neurons in a Huntington disease mouse model.
Kolodziejczyk K; Raymond LA
Neurobiol Dis; 2016 Feb; 86():62-74. PubMed ID: 26621114
[TBL] [Abstract][Full Text] [Related]
3. p35 hemizygosity activates Akt but does not improve motor function in the YAC128 mouse model of Huntington's disease.
Park KHJ; Franciosi S; Parrant K; Lu G; Leavitt BR
Neuroscience; 2017 Jun; 352():79-87. PubMed ID: 28391013
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional correlates of the pathological phenotype in a Huntington's disease mouse model.
Gallardo-Orihuela A; Hervás-Corpión I; Hierro-Bujalance C; Sanchez-Sotano D; Jiménez-Gómez G; Mora-López F; Campos-Caro A; Garcia-Alloza M; Valor LM
Sci Rep; 2019 Dec; 9(1):18696. PubMed ID: 31822756
[TBL] [Abstract][Full Text] [Related]
5. Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats.
Menalled LB; Sison JD; Dragatsis I; Zeitlin S; Chesselet MF
J Comp Neurol; 2003 Oct; 465(1):11-26. PubMed ID: 12926013
[TBL] [Abstract][Full Text] [Related]
6. Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease.
Van Raamsdonk JM; Murphy Z; Slow EJ; Leavitt BR; Hayden MR
Hum Mol Genet; 2005 Dec; 14(24):3823-35. PubMed ID: 16278236
[TBL] [Abstract][Full Text] [Related]
7. Enhanced striatopallidal gamma-aminobutyric acid (GABA)
Perez-Rosello T; Gelman S; Tombaugh G; Cachope R; Beaumont V; Surmeier DJ
Mov Disord; 2019 May; 34(5):684-696. PubMed ID: 30726572
[TBL] [Abstract][Full Text] [Related]
8. Natural history of disease in the YAC128 mouse reveals a discrete signature of pathology in Huntington disease.
Carroll JB; Lerch JP; Franciosi S; Spreeuw A; Bissada N; Henkelman RM; Hayden MR
Neurobiol Dis; 2011 Jul; 43(1):257-65. PubMed ID: 21458571
[TBL] [Abstract][Full Text] [Related]
9. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease.
Stanek LM; Yang W; Angus S; Sardi PS; Hayden MR; Hung GH; Bennett CF; Cheng SH; Shihabuddin LS
J Huntingtons Dis; 2013; 2(2):217-28. PubMed ID: 25063516
[TBL] [Abstract][Full Text] [Related]
10. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease.
Slow EJ; van Raamsdonk J; Rogers D; Coleman SH; Graham RK; Deng Y; Oh R; Bissada N; Hossain SM; Yang YZ; Li XJ; Simpson EM; Gutekunst CA; Leavitt BR; Hayden MR
Hum Mol Genet; 2003 Jul; 12(13):1555-67. PubMed ID: 12812983
[TBL] [Abstract][Full Text] [Related]
11. Effects of Exogenous NUB1 Expression in the Striatum of HDQ175/Q7 Mice.
Vodicka P; Chase K; Iuliano M; Valentine DT; Sapp E; Lu B; Kegel-Gleason KB; Sena-Esteves M; Aronin N; DiFiglia M
J Huntingtons Dis; 2016 Jun; 5(2):163-74. PubMed ID: 27314618
[TBL] [Abstract][Full Text] [Related]
12. Altering cortical input unmasks synaptic phenotypes in the YAC128 cortico-striatal co-culture model of Huntington disease.
Schmidt ME; Buren C; Mackay JP; Cheung D; Dal Cengio L; Raymond LA; Hayden MR
BMC Biol; 2018 Jun; 16(1):58. PubMed ID: 29945611
[TBL] [Abstract][Full Text] [Related]
13. Similar Progression of Morphological and Metabolic Phenotype in R6/2 Mice with Different CAG Repeats Revealed by In Vivo Magnetic Resonance Imaging and Spectroscopy.
Sawiak SJ; Wood NI; Morton AJ
J Huntingtons Dis; 2016 Oct; 5(3):271-283. PubMed ID: 27662335
[TBL] [Abstract][Full Text] [Related]
14. Polyglutamine-modulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity.
Cowan CM; Fan MM; Fan J; Shehadeh J; Zhang LY; Graham RK; Hayden MR; Raymond LA
J Neurosci; 2008 Nov; 28(48):12725-35. PubMed ID: 19036965
[TBL] [Abstract][Full Text] [Related]
15. Neuroanatomical Visualization of the Impaired Striatal Connectivity in Huntington's Disease Mouse Model.
Kim D; Jeon J; Cheong E; Kim DJ; Ryu H; Seo H; Kim YK
Mol Neurobiol; 2016 May; 53(4):2276-86. PubMed ID: 25976370
[TBL] [Abstract][Full Text] [Related]
16. Mitigation of augmented extrasynaptic NMDAR signaling and apoptosis in cortico-striatal co-cultures from Huntington's disease mice.
Milnerwood AJ; Kaufman AM; Sepers MD; Gladding CM; Zhang L; Wang L; Fan J; Coquinco A; Qiao JY; Lee H; Wang YT; Cynader M; Raymond LA
Neurobiol Dis; 2012 Oct; 48(1):40-51. PubMed ID: 22668780
[TBL] [Abstract][Full Text] [Related]
17. Non-Cell Autonomous and Epigenetic Mechanisms of Huntington's Disease.
Kim C; Yousefian-Jazi A; Choi SH; Chang I; Lee J; Ryu H
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830381
[TBL] [Abstract][Full Text] [Related]
18. Oxidative metabolism and Ca
Hamilton J; Brustovetsky T; Brustovetsky N
Neurochem Int; 2017 Oct; 109():24-33. PubMed ID: 28062223
[TBL] [Abstract][Full Text] [Related]
19. P38 MAPK is involved in enhanced NMDA receptor-dependent excitotoxicity in YAC transgenic mouse model of Huntington disease.
Fan J; Gladding CM; Wang L; Zhang LY; Kaufman AM; Milnerwood AJ; Raymond LA
Neurobiol Dis; 2012 Mar; 45(3):999-1009. PubMed ID: 22198502
[TBL] [Abstract][Full Text] [Related]
20. Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease.
Van Raamsdonk JM; Pearson J; Murphy Z; Hayden MR; Leavitt BR
BMC Neurosci; 2006 Dec; 7():80. PubMed ID: 17147801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
